| 摘要 |
<p>The invention relates to a hybrid adenoviral gene expression vector which is characterised in that it comprises at least the following elements, oriented from 5' to 3', namely: (i) a first chain of adenoviral origin, which contains a first inverted terminal repeated sequence (ITR) and a signal sequence for packing the adenovirus; (ii) a first non-coding filler sequence; (iii) a sequence corresponding to a specific tissue promoter; (iv) an alphavirus-derived cDNA chain, the sequence of which is in part complementary to an alphaviral RNA, comprising at least one sequence coding for at least one exogenous gene of interest; (v) a polyadenylation sequence; and (vi) a second adenoviral inverted terminal repeated sequence (ITR). The invention preferably relates to a hybrid adenoviral vector which comprises, by way of an exogenous gene of interest, the mammalian interleukin therapeutic gene IL-12, and more preferably still, human interleukin hIL-12. The invention also relates to the use of the hybrid vector in a method for the transfer of genetic material to a cell, particularly a tumour cell and preferably a cell expressing AFP, and to the use of same in order to induce an immune response against foreign antigens.</p> |
